These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 2476598)

  • 1. Cilazapril and enalapril inhibit local angiotensin I conversion in human veins but lack direct venodilating properties.
    Eichler HG; Blöchl-Daum B; Kyrle PA; Gasic S
    J Cardiovasc Pharmacol; 1989 Aug; 14(2):248-52. PubMed ID: 2476598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Direct angiotensin converting enzyme inhibitor-mediated venodilation.
    Zarnke KB; Feldman RD
    Clin Pharmacol Ther; 1996 May; 59(5):559-68. PubMed ID: 8646827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A review of the preclinical cardiovascular pharmacology of cilazapril, a new angiotensin converting enzyme inhibitor.
    Waterfall JF
    Br J Clin Pharmacol; 1989; 27 Suppl 2(Suppl 2):139S-150S. PubMed ID: 2527528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of ACE inhibition with cilazapril on splanchnic and systemic haemodynamics in man.
    Gasic S; Heinz G; Kleinbloesem C; Korn A
    Br J Clin Pharmacol; 1989; 27 Suppl 2(Suppl 2):225S-234S. PubMed ID: 2548552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The assessment of ACE activity in man following angiotensin I challenges: a comparison of cilazapril, captopril and enalapril.
    Essig J; Belz GG; Wellstein A
    Br J Clin Pharmacol; 1989; 27 Suppl 2(Suppl 2):217S-223S. PubMed ID: 2548551
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enalaprilat, but not cilazaprilat, increases inflammatory skin reactions in guinea-pigs.
    Andersson RG; Karlberg BE; Lindgren BR; Persson K; Rosenqvist U
    Drugs; 1991; 41 Suppl 1():48-53. PubMed ID: 1712272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biological properties of the angiotensin-converting enzyme inhibitor cilazapril.
    Natoff IL; Nixon JS; Francis RJ; Klevans LR; Brewster M; Budd J; Patel AT; Wenger J; Worth E
    J Cardiovasc Pharmacol; 1985; 7(3):569-80. PubMed ID: 2410692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of oral cilazapril and prazosin on the constrictor effects of locally infused angiotensin I and noradrenaline in human dorsal hand veins.
    Belz GG; Beermann C; Schloos J; Kleinbloesem CH
    Br J Clin Pharmacol; 1989 Nov; 28(5):608-11. PubMed ID: 2531608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative evidence of peripheral conversion of angiotensin within the human leg: effects of local angiotensin-I administration and angiotensin-converting enzyme inhibition on regional blood flow and angiotensin-II balance across the leg.
    Gasic S; Heinz G; Kleinbloesem C
    Naunyn Schmiedebergs Arch Pharmacol; 1990 Oct; 342(4):436-40. PubMed ID: 2147739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hemodynamic responses to angiotensin I in normal volunteers and the antagonism by the angiotensin-converting enzyme inhibitor cilazapril.
    Belz GG; Essig J; Wellstein A
    J Cardiovasc Pharmacol; 1987 Feb; 9(2):219-24. PubMed ID: 2436002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of angiotensin-I response by cilazapril and its time course in normal volunteers.
    Wellstein A; Essig J; Belz GG
    Clin Pharmacol Ther; 1987 Jun; 41(6):639-44. PubMed ID: 3034469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the pharmacokinetics and pharmacodynamics of perindopril, cilazapril and enalapril.
    Louis WJ; Conway EL; Krum H; Workman B; Drummer OH; Lam W; Phillips P; Howes LG; Jackson B
    Clin Exp Pharmacol Physiol Suppl; 1992; 19():55-60. PubMed ID: 1327596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical pharmacology of cilazapril.
    Kleinbloesem CH; Van Brummelen P; Francis RJ; Wiegand UW
    Am J Med; 1989 Dec; 87(6B):45S-49S. PubMed ID: 2532460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation between plasma concentration of cilazapril and haemodynamic and hormonal effects in healthy man.
    Burnier M; Mooser V; Nussberger J; Waeber B; Brunner HR
    Br J Clin Pharmacol; 1989; 27 Suppl 2(Suppl 2):189S-197S. PubMed ID: 2527532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Angiotensin-converting enzyme inhibition improves venous endothelial dysfunction in chronic smokers.
    Chalon S; Moreno H; Hoffman BB; Blaschke TF
    Clin Pharmacol Ther; 1999 Mar; 65(3):295-303. PubMed ID: 10096262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of angiotensin-converting enzyme in human hand veins.
    Chalon S; Bedarida GV; Moreno H; Tejura B; Urae A; Hoffman BB; Blaschke TF
    Clin Pharmacol Ther; 1999 Jan; 65(1):58-65. PubMed ID: 9951431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of enalaprilat on venoconstriction to norepinephrine: role of prostaglandins.
    Dzeka TN; Townley R; Arnold JM
    Cardiovasc Res; 2003 Jul; 59(1):250-6. PubMed ID: 12829196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of angiotensin-converting enzyme inhibition on arterial, venous and capillary functions in cat skeletal muscle in vivo.
    Ekelund U
    Acta Physiol Scand; 1996 Sep; 158(1):29-37. PubMed ID: 8876745
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of cilazaprilat and enalaprilat on experimental dermatitis in guinea pigs.
    Rosenqvist U; Persson K; Lindgren BR; Andersson RG
    Pharmacol Toxicol; 1991 May; 68(5):404-7. PubMed ID: 1719514
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The pharmacokinetics and bioavailability of cilazapril in normal man.
    Williams PE; Brown AN; Rajaguru S; Francis RJ; Walters GE; McEwen J; Durnin C
    Br J Clin Pharmacol; 1989; 27 Suppl 2(Suppl 2):181S-188S. PubMed ID: 2527531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.